Relates to establishing the "340B prescription drug anti-discrimination act"; prohibits pharmaceutical manufacturers and pharmacy benefit managers from discriminating against covered entities and New York state pharmacies based on participation in the drug discount program authorized by section 340B of the federal public health service act.
Summary
Bill S01913, known as the '340B Prescription Drug Anti-Discrimination Act', aims to amend the public health law in New York to prohibit discrimination against covered entities and contract pharmacies participating in the 340B drug discount program. The bill specifically targets practices by pharmaceutical manufacturers, pharmacy benefit managers, and other entities that may deny or limit access to drugs based on a pharmacy's participation in the 340B program. This legislation is intended to ensure that entities participating in the program are treated equitably and do not face additional burdens compared to those not participating.
Impact
If enacted, this bill would strengthen protections for covered entities and contract pharmacies under the 340B program, ensuring they cannot be discriminated against in terms of drug access and reimbursement conditions. It would also empower the state's health commissioner to impose civil penalties on entities that violate these provisions, thereby enhancing enforcement mechanisms within New York's public health law. This could lead to increased access to affordable medications for vulnerable populations served by these covered entities.
Sentiment
The sentiment surrounding Bill S01913 appears to be largely positive, as evidenced by the strong support in committee votes, with multiple votes showing overwhelming approval (14-1, 13-0, and 22-0). This indicates a consensus among committee members regarding the importance of protecting the 340B program and the entities involved in it.
Contention
While the bill has garnered significant support, there may be concerns from pharmaceutical manufacturers and pharmacy benefit managers regarding the implications of the proposed restrictions on their operations. These stakeholders may argue that the bill could limit their ability to manage drug distribution and pricing effectively, leading to potential financial repercussions. However, specific points of contention have not been extensively documented in the available committee discussions.
Same As
Relates to establishing the "340B prescription drug anti-discrimination act"; prohibits pharmaceutical manufacturers and pharmacy benefit managers from discriminating against covered entities and New York state pharmacies based on participation in the drug discount program authorized by section 340B of the federal public health service act.
Relates to establishing the "340B prescription drug anti-discrimination act"; prohibits pharmaceutical manufacturers and pharmacy benefit managers from discriminating against covered entities and New York state pharmacies based on participation in the drug discount program authorized by section 340B of the federal public health service act.
Prohibits any health insurer, pharmacy benefit manager, manufacturer or other third-party payor from discriminating against any 340B entity participating in a drug discount program.
Prohibits any health insurer, pharmacy benefit manager, manufacturer or other third-party payor from discriminating against any 340B entity participating in a drug discount program.
Health: pharmaceuticals; drug manufacturers from engaging in certain conduct with pharmacies participating with a 340B program; prohibit. Amends 1978 PA 368 (MCL 333.1101 - 333.25211) by adding sec. 17757c. TIE BAR WITH: SB 95'25